Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of OXP005
NCT02408978Phase 1Completed
- Sponsor
- Oxford Pharmascience
- Start
- May 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OXP005 in Rheumatic diseases and pain (2 arms), sponsored by Oxford Pharmascience. Primary endpoints: Severity of GD irritation in the stomach and duodenum as measured by the Lanza score at Day 8 and Total number of GD erosions overall at Day 8. Started May 2015; status: completed.
02
Drugs
OXP005
03
Conditions
Rheumatic diseasespain
Beyond the preview
Go deeper on NCT02408978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408978.